BACKGROUND: High circulating levels of insulin-like growth factor (IGF-I) may elevate the risk of breast cancer in premenopausal women, possibly by increasing cell proliferation and reducing apoptosis. METHODS: We conducted a nested case-control study among 35,105 Norwegian women who participated in a health screening survey, ages 40 to 42 years, and who were subsequently followed for a mean period of 4.3 years. During this period, 325 women were diagnosed with breast cancer; 647 women without breast cancer, matched on age and time of blood sampling, were selected as controls. Serum concentrations of IGF-I and its main binding protein (IGFBP-3) were measured with radioimmunoassay, and logistic regression analysis was used to adjust for relevant covariates. RESULTS: The mean age at blood collection was 41.1 years in both groups, and the mean age at diagnosis for the cases was 45.4 years (range, 40-51 years). The median IGF-I level did not differ between cases (205 ng/mL) and controls (202 ng/mL). When analyzed by categories of serum IGF-I, the relative risk for women in the highest versus the lowest quintile was 1.46 (95% confidence interval, 0.93-2.32; P(trend) = 0.15) after adjusting for serum IGFBP-3, age, and year of blood collection. The exclusion of cases that were diagnosed within 2 years after blood collection did not materially affect the results. CONCLUSION: We found only a modest positive association between serum IGF-I levels and risk of breast cancer in women younger than 50 years of age.
BACKGROUND: High circulating levels of insulin-like growth factor (IGF-I) may elevate the risk of breast cancer in premenopausal women, possibly by increasing cell proliferation and reducing apoptosis. METHODS: We conducted a nested case-control study among 35,105 Norwegian women who participated in a health screening survey, ages 40 to 42 years, and who were subsequently followed for a mean period of 4.3 years. During this period, 325 women were diagnosed with breast cancer; 647 women without breast cancer, matched on age and time of blood sampling, were selected as controls. Serum concentrations of IGF-I and its main binding protein (IGFBP-3) were measured with radioimmunoassay, and logistic regression analysis was used to adjust for relevant covariates. RESULTS: The mean age at blood collection was 41.1 years in both groups, and the mean age at diagnosis for the cases was 45.4 years (range, 40-51 years). The median IGF-I level did not differ between cases (205 ng/mL) and controls (202 ng/mL). When analyzed by categories of serum IGF-I, the relative risk for women in the highest versus the lowest quintile was 1.46 (95% confidence interval, 0.93-2.32; P(trend) = 0.15) after adjusting for serum IGFBP-3, age, and year of blood collection. The exclusion of cases that were diagnosed within 2 years after blood collection did not materially affect the results. CONCLUSION: We found only a modest positive association between serum IGF-I levels and risk of breast cancer in women younger than 50 years of age.
Authors: YongLi Ji; Tiffany Rounds; Abigail Crocker; Betsy Sussman; Russell C Hovey; Fonda Kingsley; Hyman B Muss; Judy E Garber; Marie E Wood Journal: Cancer Prev Res (Phila) Date: 2016-02-23
Authors: Nancy U Lin; Ann Vanderplas; Melissa E Hughes; Richard L Theriault; Stephen B Edge; Yu-Ning Wong; Douglas W Blayney; Joyce C Niland; Eric P Winer; Jane C Weeks Journal: Cancer Date: 2012-04-27 Impact factor: 6.860
Authors: Christopher J Moulton; Rudy J Valentine; Donald K Layman; Suzanne Devkota; Keith W Singletary; Matthew A Wallig; Sharon M Donovan Journal: Nutr Metab (Lond) Date: 2010-01-10 Impact factor: 4.169
Authors: Dana E Rollison; Anna R Giuliano; Betsy C Risendal; Carol Sweeney; David Boulware; Christine Laronga; Kathy B Baumgartner; Tim Byers; Martha L Slattery Journal: Breast Cancer Res Treat Date: 2009-11-04 Impact factor: 4.624
Authors: Roshni Rao; Veronica Cruz; Yan Peng; Amy Harker-Murray; Barbara B Haley; Hong Zhao; Xian-Jin Xie; David Euhus Journal: Breast Cancer (Auckl) Date: 2012-02-01